Chau Dang, MD, Memorial Sloan Kettering Westchester

home / authors / chau-dang-md-memorial-sloan-kettering-westchester

Articles

Chau T. Dang, MD

Dr. Dang on the Design of the BERENICE Trial in HER2+ Breast Cancer

Chau Dang, MD, Memorial Sloan Kettering Westchester
September 16th 2021

Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.

Read More

Q&A: Practical Considerations in HER2+ Breast Cancer

Q&A: Practical Considerations in HER2+ Breast Cancer

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

The Impact of Subcutaneous Option for HER2+ BC

The Impact of Subcutaneous Option for HER2+ BC

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

Clinical Outcomes in HER2+ BC: FeDeriCa and PHranceSCa

Clinical Outcomes in HER2+ BC: FeDeriCa and PHranceSCa

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

Efficacy of Fixed-Dose Subcutaneous Therapy for HER2+ BC

Efficacy of Fixed-Dose Subcutaneous Therapy for HER2+ BC

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

Administration of Dual HER2-Targeted Therapy in BC

Administration of Dual HER2-Targeted Therapy in BC

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

Dual HER2-Targeted Approaches in Breast Cancer

Dual HER2-Targeted Approaches in Breast Cancer

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

Historic Perspectives on HER2+ Breast Cancer

Historic Perspectives on HER2+ Breast Cancer

Mark Pegram, MD, Stanford Women's Cancer Center;Chau Dang, MD, Memorial Sloan Kettering Westchester;Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center
September 24th 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need